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Aims. GATA3 is a transcription factor closely associated with estrogen receptor alpha 
(ER) in breast carcinoma, with a potential prognostic utility. This study investigated the 
immunohistochemical expression of GATA3 in ER-positive and ER-negative breast 
carcinomas. 
Methods and Results. One hundred sixty six cases of invasive breast carcinomas with 
10-year follow-up information were analyzed. Positive GATA3 and ER cases were 
defined as greater than 20% of cells staining. Time to cancer recurrence and time to death 
were analyzed with survival methods. Of 166 patients, 40 were ER-negative and 121 ER-
positive. Thirty eight (23%) recurrences and 51 (31%) deaths were observed. In final 
multivariable analyses, GATA3-positive tumors had about two-thirds the recurrence risk 
of GATA3-negative tumors (hazard ratio, HR = 0.65, p = 0.395) and comparable 
mortality risk (HR = 0.86, p = 0.730). In pre-specified subgroup analyses, the protective 
effect of GATA3 expression was most pronounced among ER-positive patients who 
received tamoxifen (HR = 0.57 for recurrence and 0.68 for death) 
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Conclusion. We found no statistically significant differences in recurrence or survival 
rates between GATA3-positive and GATA3-negative tumors. However, there was a 
suggestion of a modest-to-strong protective effect of GATA3 expression among ER-




 GATA3 is one of six members of a family of transcription factors that bind the 
consensus motif A/TGATAA/G and which regulates critical steps of differentiation 
during embryonic development [1]. GATA3 is located at chromosome 10p15 [2]. GATA 
1, 2 and 3 are critically involved in myeloerythropoiesis whereas GATA 4, 5 and 6 are 
implicated in cardiac and intestinal development [3]. The binding element comprises two 
C4 zinc finger motifs shared with the steroid hormone receptor super family, and is 
highly conserved among different vertebrate and invertebrate species [1]. GATA3 
regulates lineage determination of many cell types. These include neurons of the 
sympathetic nervous system, T helper cells, the inner root sheath of hair follicles, fat 
cells, nephritic ducts of the kidney, and the ear cochleae [4, 5]. Fetal mice cannot survive 
to term without GATA3 [6]. In humans, mutations in one of the GATA3 genes lead to 
thyroid and kidney dysfunctions, and hearing abnormalities [7]. Two studies showed that 
GATA3 is necessary for mammary gland morphogenesis, luminal-cell differentiation and 
maintenance of luminal cell differentiation in adult mice [8, 9]. GATA3 expression 
occurs early in embryonic development, but only in the luminal epithelial cells, not it 
myoepithelial cells. 
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 GATA3 is a gene regulatory factor that guides immature breast cells on their 
developmental path to form luminal epithelial cells. Moreover, GATA3 is linked to two 
other gene regulatory factors, namely FoxA1 and estrogen receptor alpha [10]. GATA3 is 
normally expressed at high levels, in association with ER, in the luminal epithelial cells.  
Interestingly, the loss of GATA3 expression results in decreased ER expression. GATA3 
and ER are involved in a positive cross-regulatory loop, where each one of these factors 
is required for the transcription of the other gene. Furthermore, GATA3 and ER 
autoregulate their own expression. These mechanisms could explain the high correlation 
of GATA3 and ER expression in luminal A breast tumors [10]. Therefore, by regulation 
of ER expression, GATA3 is crucial for estradiol-stimulated progression of ER-positive 
breast cancer. Luminal A breast cancers show the highest expression of ER and GATA3. 
Luminal B tumors show significantly decreased ER and GATA3 expression while basal-
like cancers show the lowest expression of ER and GATA3 [11, 12].  
 Expression of ER is currently the best approach to predicting whether or not 
breast carcinoma will respond to hormonal therapy.  However, approximately 30 % of 
ER-positive breast cancers do not respond to hormonal therapy. In breast cancer, it has 
been shown that higher expression of GATA3 predicts a better prognosis and GATA3 
expression has been shown to be a predictor of hormonal response [13-15]. The goal of 
this study is to correlate GATA3 expression with recurrence and survival in ER-positive 
breast cancer patients with 10 years of follow-up. 
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2. Materials & Methods 
 Formalin fixed paraffin-embedded tissues of consecutive breast 
carcinomas were obtained from the files of the Department of Pathology of Thomas 
Jefferson University. All breast tissue was formalin fixed appropriately following a 
protocol for breast samples that was established in our Institution to avoid false negative 
or positive staining. All cases had been treated with surgery (most by lumpectomy alone 
and 25% with mastectomy); the majority of these patients had also received radiotherapy, 
and some patients had received hormonal therapy and/or chemotherapy. The cases were 
stained with GATA3 monoclonal antibody (Santa Cruz Biotechnology, 1:250 dilution) 
with microwave antigen retrieval pretreatment in citrate buffer as previously described 
[14]. Positive and negative controls were used in each run. The study was approved by 
the Thomas Jefferson University Internal Review Board. 
 We analyzed time to recurrence and time to death via survival methods, 
specifically the Kaplan-Meier approach and the logrank test, as well as Cox proportional 
hazards regression. The final multivariable model included five markers (GATA3, ER, 
PR, Ki67, and p53) irrespective of their statistical significance; other variables were 
retained if their p-value was less than 0.1. For the main analyses, the expression of all 
five markers was dichotomized a priori as nuclear staining in 0-20% versus 21-100% of 
the cells. We also explored the significance between lower and higher cut points (greater 
than or less than 20%) for GATA3 as well as its expression as a continuous predictor. 
Additional analyses explored different cut points, as well as the use of the markers’ 
expression as a continuous predictor. GATA3 immunohistochemical scoring was 
performed blinded by two pathologists (V.C. and J.P.P.). GATA3 nuclear staining of any 
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intensity was considered positive when present in 20% or more of the tumor cells. 
Statistical analyses were carried out in SAS 8.2 (SAS Institute Inc., Cary, NC). 
 
3. Results 
 Information from 188 patients was reviewed, and the final analysis sample 
consisted of 166 patients with available data for key variables (including follow-up dates 
and GATA3 expression). Clinical follow-up ranged between 4 and 133 months (median = 
115 months). The mean age at diagnosis was 62 years (range, 27 to 89 years) so that all 
age groups were represented in the study. 
 Tables 1 and 2 present details of the study patients’ tumor and treatment 
characteristics, respectively. The majority of tumors were invasive ductal carcinomas 
(IDC) and tumor size ranged from 0.4 to 10 cm. The vast majority of patients presented 
with stage 1 or stage 2 (AJCC) carcinomas.  Of the 125 T1 invasive carcinomas, 68 
(54%) were GATA3-positive. Of the 31 T2 invasive carcinomas, 23 (74%) were 
GATA3-positive. Of the seven T3 tumors, 6 were invasive ductal carcinomas and 1 was 
invasive lobular carcinoma. Of these seven T3 tumors, one tumor (invasive ductal 
carcinoma) was ER-positive and GATA3-positive. The remaining tumors were all ER-
negative and GATA3-negative. 
Most of the tumors stained positive for both ER and GATA3 (Figures 1-6). There 
was a very strong correlation between GATA3 and ER expression. Of the 93 tumors that 
were ER-positive/GATA3-positive, expression tended to be very high (i.e., 80-90%) for 
both markers. Of the ER-negative tumors, all but 2 were also GATA3-negative, while of 
the 121 ER-positive patients, 93 (77%) were also GATA3 positive. There were 12 cases 
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of invasive lobular carcinoma.  Eleven of the twelve invasive lobular carcinomas were 
ER-positive. Of these 11 tumors, 6 were GATA3-positive and 4 were GATA3-negative 
(one paraffin block had insufficient tissue for GATA3 staining). One invasive lobular 
carcinoma was ER-negative and GATA3-negative. The percentage of ER-positive, 
GATA3-positive tumors is slightly lower for invasive lobular than invasive ductal 
carcinomas, 60% and 77%, respectively.  
3.1 GATA3 and Recurrence  
 A total of 38 (23%) cancer recurrences were observed, including 13 local, 1 
regional, and 24 metastatic. Among the 38 patients, time from surgery to recurrence 
ranged from 4.4 to 94.1 months (median = 19.5 months). Of the 121 ER-positive tumors, 
93 were GATA3-positive and 28 were GATA3-negative. Of the 45 ER-negative tumors, 
43 were GATA3-negative and 2 were GATA3-positive. Overall, GATA3-positive tumors 
had about half the recurrence risk of GATA3-negative tumors (hazard ratio, HR = 0.52, p 
= 0.041). However, because of the strong correlation between GATA3 and ER, both of 
these markers should be considered together. Figure 7 shows the Kaplan-Meier plot of 
recurrence, by GATA3 and ER status. Because there were only two tumors that were ER 
negative and GATA3-positive (results not shown) the GATA3 effect could only be 
evaluated among ER-positive tumors. In this group, GATA3 remained somewhat 
protective, although the effect was attenuated (HR = 0.66, p = 0.363). 
 The results of the final multivariable Cox model (that omitted the two GATA3-
positive and ER-negative tumors) are shown in Table 3. Neither GATA3 nor ER were 
significant, although positive expression (>20%) of both of these markers was associated 
with somewhat lower risk of recurrence. In contrast, PR and Ki67 expression were both 
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significantly associated with higher risk of recurrence, as was larger tumor size. GATA3 
was still not significant when its expression was categorized as 0-20%, 21-60%, and 61-
100% (p = 0.231), although there was some indication that a higher positive cutpoint 
might be more appropriate for this marker’s expression (results not shown). 
3.2 GATA3 and Mortality 
 A total of 51 (31%) deaths were observed among the study’s patients, with times 
from surgery to death ranging from 5.4 to 114.2 months (median = 36.5 months). The 
patterns seen with mortality were similar to those seen with tumor recurrence but of 
diminished magnitude. Overall, GATA3-positive tumors showed only a small survival 
benefit compared to GATA3-negative tumors (HR = 0.75, p = 0.310). Figure 8 shows the 
Kaplan-Meier plot of time to death, by GATA3 and ER status. When both markers were 
taken into account, GATA3 expression among ER positive tumors was not associated 
with mortality (HR = 0.87, p = 0.728). 
 The results of the final multivariable Cox model (which omitted the two tumors 
that were GATA3-positive and ER-negative) are shown in Table 4. Neither GATA3 nor 
ER were significantly associated with survival, nor were any of the other markers. These 
findings did not change when GATA3 expression was categorized as 0-20%, 21-60%, 
and 61-100% (p = 0.942), or when the markers’ degrees of expression were used as 
continuous predictors (p = 0.766 for GATA3). GATA3 was also not significant in 
analyses restricted to the first five years of follow-up after surgery (p = 0.785). 
 
3.3 GATA3 and tamoxifen 
 We conducted pre-specified subgroup analyses among the 121 ER-positive 
patients to evaluate the potential relationship between hormonal therapy and GATA3. In 
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this group, 46 patients (38%) had recorded tamoxifen treatment and the remaining 75 
(62%) did not. In multivariable analyses of recurrence, we found no significant relation 
between GATA3 and hormone treatment (p = 0.536). The GATA3 protective effect 
appeared stronger among those who had received tamoxifen (HR = 0.57, p = 0.476) than 
among those who had not (HR = 1.14, p = 0.853).  The same pattern was present for 
mortality. The relation between GATA3 and hormone treatment was not significant (p = 
0.507), but the GATA3 protective effect was more pronounced in the tamoxifen group 
(HR = 0.68, p = 0.540) compared to ER-positive patients not treated with tamoxifen (HR 
= 1.23, p = 0.743). 
 
4. Discussion 
 GATA3 has been shown to be necessary for mammary gland morphogenesis, 
luminal cell differentiation and also for maintenance of luminal cell differentiation in 
mice [8, 9]. GATA3 and ER are involved in a positive cross-regulatory loop, where each 
one of these factors is required for the transcription of the other gene. Furthermore, 
GATA3 and ER autoregulate their own expression and one would expect that GATA3 
expression would be informative of the functional status of the ER pathway [10]. In well-
differentiated, low-grade carcinomas such as luminal A breast cancers both ER and 
GATA3 are expected to show strong expression. GATA3 has been shown to actively 
participate in the differentiation of luminal cells and its lack of expression is indicative of 
increased proliferation and the development of less differentiated tumors [16]. However, 
an unresolved question regarding GATA3 is its prognostic significance in patients with 
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breast cancer with long follow-up information. The role of GATA3 in patients with ER-
positive tumors has not been fully investigated. 
 The current study includes consecutive invasive breast carcinomas and correlates 
ER and GATA3 expression with long-term recurrence and survival follow-up. In our 
study, there was a consistent expression of GATA3 in ER-positive tumors (77% of the 
cases). This finding is evidence that GATA3 expression is ER-dependent in most breast 
cancers. Furthermore, all but two of the ER-negative carcinomas were also GATA3-
negative, implying that GATA3 expression is dependent upon a functioning and intact 
ER pathway. Consequently, any predictive utility of GATA3 expression (beyond that of 
ER expression) essentially applies to ER-positive patients only. 
 Among 121 ER-positive patients, we found no significant association of GATA3 
expression with either recurrence or survival, although we did confirm the importance of 
known pathological parameters, such as tumor size for survival and of the proliferation 
rate (as detected by Ki67) as a predictor of recurrence. Mehra et al studied 139 
consecutive invasive breast carcinomas and measured GATA3 expression by 
immunohistochemistry [15]. The overall survival in that study was comparable to the 
experience of the patients in our study (about 75-80% for 5-year survival, and 70% for 
10-year survival). Of the 51 deaths in our study population, 17 patients were confirmed to 
have died as a result of metastatic breast cancer. We were unable to verify that other 34 
deaths were a direct result of the breast cancer. However, Mehra et al found a very strong 
and significant protective effect of GATA3 expression, with estimated 10-year survival 
of 55% for low GATA3 and 84% for high GATA3 (hazard ratio = 0.12, p = 0.05) [15]. In 
contrast, in our study, we estimated a much weaker and non-significant difference 
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between GATA3-positive and GATA3-negative tumors (hazard ratio = 0.86, p = 0.73). 
Nevertheless, given the relatively wide confidence intervals, the findings of the two 
studies are not inconsistent. The discrepancy may also be partly explained by differences 
of study populations and methods for the assessment and scoring of GATA3 expression. 
We note, however, that our results were not sensitive to different cut points for GATA3 
positivity. When GATA3 was examined as a continuous variable and the cut-off points 
moved, the recurrence and survival did not change. 
 Since any effect of GATA3 is most likely related to tumor sensitivity to hormonal 
regulation, it is reasonable to expect a more pronounced effect among ER-positive 
patients treated with tamoxifen. In a previous pilot study of 28 ER-positive patients who 
had received hormone treatment, we found that GATA3-positive tumors had almost 90% 
lower risk of being hormone unresponsive than GATA3-negative tumors [13]. Our 
current study included 121 ER-positive patients, of whom 46 had received hormone 
therapy. We found that the GATA3 effect was most pronounced among the latter group, 
with GATA3-positive tumors associated with better prognosis than GATA3-negative 
tumors. This finding was consistent with the results of our earlier study, although 
GATA3 expression was associated with only a 43% lower risk of recurrence and 32% 
lower risk of mortality. If this signifies a true predictive utility of GATA3, it may be a 
reflection of a functioning ER pathway and therefore a more predictable response to 
tamoxifen. Forty six of 121 (38%) patients whose tumors were ER-positive were 
confirmed treated with tamoxifen. Presumably, the vast majority of patients with ER-
positive tumors in 1995 received tamoxifen. However, we were unable to verify this 
information in the medical records. 
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 A recent study by Voduc et al looked at GATA3 expression by 
immunohistochemistry in breast cancer[17]. They studied 3119 cases of invasive breast 
carcinoma using tissue 0.6 mm tissue microarrays. The GATA3 antibody, like in our 
study was from Santa Cruz Biotechnology, but at a dilution of 1:20 (1:250 in our study). 
They scored GATA3 staining as negative (0) if less than 5% of nuclei stained above 
background, moderate (1+) if 5% to 20% of nuclei were stained, and strong (2+) if >20% 
were stained. Invasive carcinomas that stained 0 were considered negative while tumors 
that were 1+ (5-20% nuclear staining) or 2+ (20% nuclear staining) were considered 
positive. Overall, our study has a slightly lower percentage of overall GATA-3 positivity 
(58% vs. 68%). Interestingly, our study had a higher rate of GATA3 positivity in ER-
positive tumors (77% vs. 39%). Although, the GATA3 positivity was slightly differently 
defined from our study, Voduc et al also showed that GATA3 expression is tightly 
related to ER expression but lacks independent prognostic value. 
 Another study also showed a high correlation between ER and GATA3 using 
gene expression profiling and applied it to different data sets [18]. In addition, that study 
reported genes induced by GATA3 present in the luminal/ER-positive gene cluster. A 
group of tumors in this study with good outcome were better differentiated and expressed 
a subset of estrogen- and GATA3-related genes. Consideration should be given to 
patients that are ER-positive but GATA3-negative to alternative therapies instead of 
tamoxifen. Knowing the status of GATA3 by immunohistochemistry may help refine the 
optimal therapeutic approach for these patients. 
 In summary, in this study of consecutive patients with invasive breast cancer and 
long follow-up, GATA3 expression did not confer a statistically significant advantage 
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with respect to recurrence or survival. However, there was some indication of a 
protective GATA3 effect in the subset of patients with ER-positive tumors who were 
treated with tamoxifen. 
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Figure 1. Hematoxylin and eosin (400X) 
Figure 2. ER positive (400X) 
Figure 3. GATA3 positive (400X) 
Figure 4. Hematoxylin and eosin (400X) 
Figure 5. ER positive (400X) 
Figure 6. GATA3 negative (400X) 
Figure 7. Kaplan-Meier analysis of time to recurrence 
Figure 8. Kaplan-Meier analysis of time to death 
Table 1. Tumor characteristics of the entire study sample 
 
Table 2. Treatment characteristics of the entire study sample 
 
Table 3. Multivariable Cox regression results for time to tumor recurrence 
 
Table 4. Multivariable Cox regression results for time to death 
 
 
